Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.ARCHER trial (acute myocarditis) completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales.MAVeRIC trial (recurrent pericarditis): Promising early results, full data in November 2024; potential approval by 2027, targeting $609M peak sales.

Here's why.

1. Focus on Energy Storage

• Both companies operate in the energy storage sector, developing technologies that enable the storage and distribution of energy, crucial for stabilizing renewable energy sources like wind and solar.
• FCEL specializes in fuel cell technology, converting fuels like hydrogen into electricity and heat, whereas EOSE produces zinc-based batteries designed to store and discharge energy over several hours, which is particularly useful for grid stabilization.

2. Sustainability and Clean Energy

• FCEL and EOSE are both committed to reducing the environmental impact of energy production. FCEL’s fuel cells offer a lower-emission alternative to traditional energy sources by using fuels such as biogas or hydrogen, while EOSE’s zinc-based batteries provide a safer, non-toxic alternative to lithium-ion batteries, which are more common but less sustainable in terms of resource extraction and disposal.

3. Target Markets

• Both companies target similar markets, including utility companies, commercial and industrial sectors, and renewable energy projects. Their technologies are designed to support larger-scale applications that require reliability and sustainability, such as microgrids and large-scale energy storage solutions for utility providers.

4. Product Differentiation in Energy Storage

• While both focus on energy storage, they have distinct approaches: FCEL’s fuel cells are advantageous for consistent energy production with low emissions and can be integrated with existing infrastructure. EOSE’s zinc-based batteries offer long-duration storage solutions to help utilities manage energy flow during high-demand periods, especially for renewable energy sources​.

5. Government and Policy Influence

• Both companies rely on supportive energy policies, federal incentives, and funding initiatives to expand operations and innovate. Initiatives like the U.S. Inflation Reduction Act benefit FCEL and EOSE by providing tax credits and funding opportunities for clean energy projects, which help accelerate their production capacity and market reach.

These similarities reflect the growing emphasis on clean energy infrastructure and the need for diverse, scalable storage solutions in the transition to renewable energy.

The similarities are there:

Both are renewable energy stocks - they focus on moving away from Fossil Fuels.

The past five months has seen a 130% increase for EOSE from below a dollar. FCEL currently sits at under a dollar. It's the next one to make the move up. One to get in now in my opinion.

Globalstar (GSAT) saw its stock surge as much as 64% in pre-market trading on news that it expanded its agreement with Apple (AAPL, Financial). The stock later settled at a 45% gain. This new service agreement involves Globalstar providing enhanced mobile satellite services to Apple, which includes a new satellite constellation, additional ground infrastructure, and increased global licensing. The enhanced network will be managed by a unit within Globalstar SPE.

As part of this agreement, Apple will prepay Globalstar up to $1.1 billion to fund approved capital expenditures related to the expanded Mobile Satellite Services (MSS) network. These funds will be disbursed quarterly during the construction phase. Globalstar SPE will use these funds and proceeds from stock sales to cover costs for the MSS network expansion, including construction and launch costs. Additionally, Globalstar will allocate funds to repay its 13.00% senior notes due in 2029, as outlined in the "2024 Prepayment Agreement."

Furthermore, Apple has agreed to purchase 400,000 Class B shares of Globalstar SPE, representing 20% equity, for $400 million. The payment is expected around November 5, 2024, subject to closing conditions. Globalstar projects that its annual revenue in the first year after the satellite service expansion will more than double the annualized level of 2024

𝑻𝒂𝒍𝒌 𝒂𝒃𝒐𝒖𝒕 𝒚𝒐𝒖𝒓 𝒅𝒂𝒊𝒍𝒚 𝒑𝒍𝒂𝒚𝒔 𝒂𝒏𝒅 𝒄𝒐𝒎𝒎𝒆𝒏𝒕 𝒐𝒓 𝒑𝒐𝒔𝒕 𝒕𝒉𝒊𝒏𝒈𝒔 𝒉𝒆𝒓𝒆 𝒕𝒉𝒂𝒕 𝒅𝒐 𝒏𝒐𝒕 𝒘𝒂𝒓𝒓𝒂𝒏𝒕 𝒂𝒏 𝒂𝒄𝒕𝒖𝒂𝒍 𝒑𝒐𝒔𝒕.

​

𝒌𝒆𝒆𝒑 𝒊𝒕 𝒄𝒊𝒗𝒊𝒍 𝒑𝒍𝒆𝒂𝒔𝒆

I am the last one to bash a stock, but I see on Reddit, Twits, Yahoo a coordinated effort to pump MYNZ.

• MYNZ
  • They have a good product. Nobody doubts that
  • They will approve a 1-2 to 1-100 reverse split soon (see Sec)
  • They have 900k in cash, barely enough for a year
  • Their products launch in 2026 EU /2027 USA (see their corporate deck)
    • IF they find funding this stock might run to 1$. Sure.
• Pumpers
  • Likely from the Philippines
    • Their English use is somewhat Tagalog/English
    • Their Reddit accounts somehow post on Philippine subs.
    • On Yahoo countless accounts have popped up that all posted 1 comment on stock A. The second comment on stock B
    • https://finance.yahoo.com/quote/4TO.SG/community/

Again. I am not saying the company is bad, not saying the stock has no chance. BUT, the coordinated effort to pull in unwitting retail is disgusting. The number of accounts, the number of posts over various platforms, tells me that this can not be done by a single person.

Nex-Gen energy has risen about 472% over the last 5 years on part because of the revival in Nuclear Energy and the scaling of their Rook 1 Uranium Mine in Canada. Once fully operational, analysts expect roughly 2B in free-cashflow annually assuming annually output of 30M pounds and a market price of $85.00 per pound Uranium.
Right now construction hasn't been approved and the company is waiting on the final environmental approval so that they can begin.
Leading up to this decision short interest has soard to record levels implying that short-sellers don't believe they will get the final approval.
Leading up to this decision short interest has soared to record levels implying that short-sellers don't believe they will get the final approval.
Binary Outcome
They Get Final Mine Approval
They Get Denied Mine Approval
Short demand is extremely high at 46%
Other Competitors/Peers in the Uranium Space are much lower with Cameco short demand at only 5.60%
Short Interest In Peer Stocks
Cameco $CCJ: 5.60%
$UEC: 28%
As seen above, Nex-Gen Energy has the greatest short demand in the industry
Factors To Cause the Squeeze
Since Short Squeezes usually have big catalysts that break open the dam of short-covering, lets talk about to Triggers that could cause this.

1. Approval to start Mine Construction.

If approved, most investors believe the stock will soar and if Construction is not approved, most believe it will crash. An approval announcement is expected before end of the year. With the approval, analysts will upgrade the stock will may cause more institional investors to buy more
Currently 15 Analysts are covering the stock with all 15 issuing a buy rating.
2. Uranium Price Surge to $150-250 per Pound
If Uranium surges to $150 a pound, Nex-Gen will reap the most benefits. This is because their competitors sell forward their future production and are overly hedged. If Uranium suddenly surges to $150 a pound, Cameco which has most of their future 5 year production already pre-sold would still only get between $50-$80 per pound of Uranium.
Nex-Gen however has pureplay exposure and hasn't sold a single pound of their future production. That means they get all of the upside of a U rally as well as all of the downside. Analysts assume 2B in Free-cashflow annually at $85 per pound of uranium for the entire mine life. If Uranium goes to $150-$200, their freecashflow would almost triple and could be around 6B annually. This of course would cause a price rally.
3. Takeover Offer
easy to explain. If they were acquired by a Major mining company, the price would rally towards to acquisition offer. There's speculation online on this but really it's anyones guess.
Conclusion the Mine approval was expected in August -September but governments being governments, the approval was delayed and likely to occur in Q4. This is the timing element of why I think We could see a breakout.
Disclosure: I own shares in the Stock and Other Uranium stocks. I also bought some call options on $NXE.

The Globe and Mail reports in its Wednesday, Oct. 23, edition that National Bank Financial analyst Don DeMarco has reaffirmed his "outperform" recommendation for Aya Gold & Silver. The Globe's David Leeder writes in the Eye On Equities column that Mr. DeMarco trimmed his share target by a loonie to $23. Analysts on average target the shares at $22.78. Mr. DeMarco says in a note: "Only pure-play silver producer on the TSX, with sight lines for NAV expansion vis-a-vis Zgounder plant ramp-up to 2,700 tpd [tons per day] (from current 700 tpd), with first pour achieved in early July. Drives peer-leading production CAGR, peaking at nine million oz in 2028 per the Zgounder feasibility study (FS; December 2021), over four times the FY23A of two million oz Ag. resource accretion compelling with visibility for 150 million oz (NBF est., from the current 103 million). Strong operations with a FY23 guidance beat, while mining rates and throughput buoyant, lending derisking and confidence ahead of expansion completion." The Globe reported on July 23 that Desjardins Securities analyst John Sclodnick had reiterated his "buy" recommendation for Aya Gold & Silver. The shares could then be had for $15.09.

Tier One Silver Inc. is pleased to report new channel sampling results from its priority silver-gold corridors Cambaya I and Cambaya II. The Cambaya structural corridors, located in the northeast area of the property, represent highly prospective precious metals target areas, identified through extensive surface sampling.

In comparison with other targets within the property, Cambaya is higher in topography, (approximately 2,400 meters above sea level ("masl")), higher in stratigraphy (Toquepala volcanic), and is believed to be located in the upper part of the epithermal system due to the occurrence of more extensive high-grade precious metal samples and high arsenic anomalies (>100ppm). The presence of lower-temperature silica and quartz vein coliform textures accompanies this.

Peter Dembicki, CEO and Director of Tier One commented, "The Curibaya project represents extensive high-grade silver veins and rock samples. The work we have completed to date at the Cambaya I, II, and Zone 1 targets supports our thesis that we are targeting the preferred precious metals zonation of an epithermal system. The recent channel samples expand our target area by 350m in width; the Cambaya corridors now have a total of 1.75 km x 950m area of prospective precious metals zonation with grades up to 8,950 g/t Ag."

"We have been patient with our anticipated next phase of drilling as a result of a weaker silver market which is finally improving. We are looking forward to our next drill program to test our most prolific and prospective targets within Cambaya."

The Company's recent surface exploration program was designed to expand the highly prospective precious metals targets and enhance the thesis that Cambaya sits at the preferred zone of an epithermal system. The program consisted primarily of channel sampling and mapping and was successful in delineating additional drill targets for a drill program anticipated for later this year. At Cambaya I, 48 samples were taken from 10 trenches in 200m x 200m areas. At Cambaya II, 53 samples were taken from 17 trenches, in 250m x 500m areas.

Hi Penny traders,

I have compiled a table with early November catalysts; feel free to use the full version - https://biopharmawatch.com/

Have a great day ahead and safe trading! :)

Cheers!

𝑻𝒂𝒍𝒌 𝒂𝒃𝒐𝒖𝒕 𝒚𝒐𝒖𝒓 𝒅𝒂𝒊𝒍𝒚 𝒑𝒍𝒂𝒚𝒔 𝒂𝒏𝒅 𝒄𝒐𝒎𝒎𝒆𝒏𝒕 𝒐𝒓 𝒑𝒐𝒔𝒕 𝒕𝒉𝒊𝒏𝒈𝒔 𝒉𝒆𝒓𝒆 𝒕𝒉𝒂𝒕 𝒅𝒐 𝒏𝒐𝒕 𝒘𝒂𝒓𝒓𝒂𝒏𝒕 𝒂𝒏 𝒂𝒄𝒕𝒖𝒂𝒍 𝒑𝒐𝒔𝒕.

​

𝒌𝒆𝒆𝒑 𝒊𝒕 𝒄𝒊𝒗𝒊𝒍 𝒑𝒍𝒆𝒂𝒔𝒆

Military Metals ($MILI.CN) has had a crazy 2024 so far. The stock has gone from $0.055 to $0.99 for a 1700% gain because of Antimony.

Antimony is a critical mineral due to its essential role in industrial & defence applications. Antimony prices have doubled this year due to export restrictions from China. The concentration of antimony production has raised concerns about potential supply restrictions as China is the largest producer of the world’s antimony supply.

Another company focused on Antimony that can help the supply problem is Bolt Metals Corp ($BOLT.CN).

Bolt has the New Britain Antimony Project, a 2,400-hectare property located in British Columbia. This site is a diamond in the rough as it is pretty much untouched by modern exploration, although historical exploration results have been strong showing 10.4% antimony.

Bolt recently closed its private placement on October 29th, raising $544,500, so we could see some
exploration activity at this property sometime soon now that they have the funds for it.

After seeing what Military Metals' stock has done this past year, I think it's worth keeping an
eye on Bolt's stock once they start exploration at the New Britain Project.

$BOIL.CN $BEOLF Beyond Oil, an innovator in the food tech sector, continues to expand its global footprint. The company has recently secured a significant order for 16 tons of its product from an Eastern European franchisee of a globally renowned fast-food chain. This order marks a milestone in Beyond Oil's strategy to disrupt the food oil industry worldwide.

According to the announcement, the sale follows a successful pilot program conducted by the franchisee. Beyond Oil's product addresses health concerns associated with fried foods while enhancing sustainability and reducing operational costs for food-processing companies. The company's solution aims to mitigate cancer and cardiovascular risks in everyday food consumption.

CEO Jonathan Or emphasizes the company's commitment to penetrating larger markets through successful pilots and initial sales with global chains. By targeting new pilots and expanding into international markets, $BOIL.CN $BEOLF aims to accelerate its pace of expansion and establish a more significant market presence.

FULL ORIGINAL CONTENT LINK: https://finance.yahoo.com/news/beyond-oil-expands-sales-eastern-113000485.html

This post is not intended to serve as financial or investment advice of any kind. This post was shared on behalf of Beyond Oil. We are compensated for our News and coverage sharing services. Some of the content we share itself may include paid content and we advise to read the fine print inside each article.

Globalstar is planning to launch up to eight satellites in 2025 to replenish its Low-Earth Orbit (LEO) constellation. The satellites will be launched by SpaceX and are intended to support Apple’s satellite emergency messaging service.

Here are some details about the launch: Contract: Globalstar contracted SpaceX to launch the satellites for $64 million.

Satellites: The satellites are being built by MDA, a Canadian manufacturer, and Rocket Lab is supplying the satellite bus.

Funding: Apple is paying for 95% of the launch and manufacturing costs, and is also lending Globalstar $252 million.

Launch window: Globalstar aims to deploy the satellites before the end of 2025.

Launch failure: Globalstar plans to launch additional satellites within months of a launch failure to maintain service quality and safety

Globalstar’s constellation will consist of 48 LEO satellites, with four spares in orbit. The system’s software is located on the ground, which makes it easier to maintain and upgrade.

Hey it’s me!

It’s about that special time to get ready for our annual run up to / around MLK

Why? It just happens cuz it happens 🧙‍♂️🔮 most of the time.

Just look at 5 year chart and look for activity up to and around MLK / Juneteenth

A reminder went on my phone so I have been buying it up a bit at a time

2m float, it’s some fledgling crypto miner nowadays. Historically limited volume so it doesn’t take much to build up a relvol spike

Best of luck and happy trading! 👋

Gorilla technology ticker GRRR (Nasdaq)

From: https://www.newsfilecorp.com/release/228173/Gorilla-Announces-Strong-Outlook-for-2024-and-Sets-Breakthrough-Growth-for-2025

🔹 2024 Projections: ✅Revenues of $72 million ✅EBITDA margin > 20% ✅Net income > $10 million ✅Backlog of $93 million in signed contracts

🔹 2025 Outlook: ✅Revenues to surpass $90 million ✅Net income > $15 million

🔹 Innovation: ✅Launched Gorilla Intelligent Network Director with strong market demand

🔹 Share Repurchase: ✅Acquired 1.1 million shares in September, reflecting confidence in our stock value

Spectral AI ($MDAI) coming out with yet another positive news report, beating timeline expectations yet again with their burn study finishing up in 2024 instead of early 2025. Expect topline study results to be very good in December since their other real world experience in the UK has had nothing but raving reviews as shown in their ITV broadcast a week ago.

Ultimately, all of this news is pointing to the DeepView imaging platform to be a product and commercial success. Hop on the uptrend into earnings on 11/6 and into the US topline study results this December when the rest of the market realizes that hospitals and burn centers will rush to acquire this revolutionary technology.

My target is >$2 by end of year.

MIlitary Metals $MILIF $MILI

"Based on historic resource, Trojarova is one of the largest unminded Sb projects globally"

Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "Military") is pleased to announced that it has entered into a definitive agreement with 1509149 B.C. Ltd., a wholly-owned subsidiary of the Company, 1458205 B.C. Ltd. (the "Target"), and the controlling shareholder of the Target pursuant to which the Company will acquire 100% of the issued and outstanding common shares in the capital of the Target (the "Target Shares") by way of a three-cornered amalgamation (the "Amalgamation").

"As we acquire this premier antimony project in Slovakia with historical resources, we're taking a transformative step to strengthen Europe's access to essential raw materials. With a well established, rich mineral base, this brownfield site enables us to work towards a reliable domestic antimony supply when Europe faces mounting supply chain pressures," said CEO Scott Eldridge*. "This acquisition reflects our commitment to reducing reliance on Chinese imports, ensuring stability for the European market, and empowering the West to drive a more resilient, self-sufficient future for critical materials."*

MIlitary Metals $MILIF $MILI

About the Target

The Target owns three brownfield projects in Slovakia. Of the three projects, Trojarova is the most advanced ("Trojarova"). Located in western Slovakia, it potentially hosts one of the European Union's most significant known primary antimony deposits. 63 holes were historically completed into the deposit during the 1980-1900s over a strike length of 1.5 kilometers, along with nearly 1.7 kilometers of underground workings; the deposit hosts historical (non-compliant) antimony and accessory gold resources classified in the Soviet era Russian classification system.

Additionally, Military has acquired both a tin and second antimony property in Slovakia. The tin property ("Medvedi-Potok"), likewise features significant historical drilling, underground development, and features a historical (non-compliant) tin resource. The Tiennesgrund antimony property features over two dozen small underground workings along its 10-kilometer length where historical production is reported.

Consideration for the acquisition of 100% of the Target Shares comprises 10,000,000 common shares in the capital of the Company (the "Company Shares"), at a deemed issuance price of $0.56 per Company Share, valued at a sum of CAD $5.6 million. The Company will also assume the Target's obligations in respect of its outstanding share purchase warrants, which will provide holders the right to acquire up to 3,499,997 Company Shares at an exercise price of $0.10 per share.

"The Trojarova antimony project is potentially one of Europe's most significant primary antimony deposits. We've experienced an unprecedented rise in the antimony price increasing from $11,000 USD per tonne, to a current spot of approximately $34,000. Increased trade wars and geopolitical tensions have placed stronger importance on this strategic metal with multiple applications," said CEO Scott Eldridge. "The EU's Critical Raw Materials Act has opened multiple financing sources from local European institutions to foster the development of strategic metals within Europe's boarders."

Antimony, a vital component in everything from battery technologies to advanced military applications such as night vision and infrared sensors, is classified as a critical mineral by the United States, Canada, the European Union, and the United Kingdom. Currently, over 90% of global antimony reserves are concentrated in China, Russia, and Tajikistan. Military seeks to target antimony with the goal of contributing to the global antimony supply, and filling a gap that is present in the ability of Western countries to obtain this critical mineral.

MIlitary Metals $MILIF $MILI

About the Projects

Discovered in the late 1970s, Trojarova was the focus of extensive surface and underground exploration from 1983 to 1995, with 63 core holes for a total of 14,330m, and 1.7km of underground workings completed. Efforts continued over the years as additional trenches were dug and holes were drilled. Starting in 1990, underground development work began ultimately comprising a 300-meter-long adit connected to a 700-plus meter-long drive in the footwall of the mineralized zone with seven crosscuts into the mineralized zone for sampling purposes. These efforts culminated in a multi-volume study comprising drill logs, analyses, drill plans, maps and sections, deposit model studies, petrographic studies, metallurgical studies and more, culminating in a multi-volume compendium of reports produced by the Slovak Geological Institute published in 1992 (the "1992 Report"). Upon completion of the Amalgamation, the Company will move forward to verify this historical estimate by confirmation drilling so that it is able to classify mineral resources at Trojarova as current, in accordance with National Instrument 43-101. The historical estimate at Trojarova was classified using the Slovak version of the newly post-Soviet Russian classification system, which is not directly comparable to or compatible with the western system as defined by the Canadian Institute of Mining, Metallurgy & Petroluem ("CIM Definition Standards for Mineral Resources & Mineral Reserves").

The 1992 Report contains a table featuring 10 alternate historical resource estimates, five focused on the antimony component of the mineralized system and five on its gold component, each group of five featuring decreasing tonnage at increasing grade for antimony and gold, respectively:

MIlitary Metals $MILIF $MILI

Historical alternate resource estimate scenarios for Trojarova

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10818/228324_9c2d07525482cbe0_001full.jpg

The Slovak Geological Institute, the state agency that carried out all exploration and underground development work at Trojárová, classified the resource as "P1" in the Slovak version of the Russian classification system. P1 is closest within the Canadian Institute of Mining, Metallurgy & Petroleum's ("CIM") classification system to "Inferred Mineral Resources," which is defined by the CIM as that part of a Mineral Resource for which quantity and grade or quality are estimated on the basis of limited geological evidence gathered through appropriate sampling techniques from locations such as outcrops, trenches, pits, workings and drill holes.

Considerable work remains to be completed before it will be possible to classify mineralization documented at Trojarova as current mineral resources. The historical drill logs need to be translated and transcribed into a logging format suitable for resource estimation purposes. All collar locations along with the underground maps need to be digitized and georeferenced. Depending upon the assessed quality and reliability of these data, it will be possible for a resource estimation geologist to determine the extent of confirmation drilling necessary so that mineralization documented at Trojarova can be classified as current mineral resources. A qualified person has not done sufficient work to classify the historical estimate as current mineral resources or mineral reserves. Military is not treating the historical estimate as current mineral resources or mineral reserves.

The Tiennesgrund antimony project, located in eastern Slovakia, comprises a 10-kilometer-long license covering a large, fault/shear-hosted antimony-gold vein system hosting multiple adits and a long artisanal-scale mining history. The nearby Medvedi-Potok property hosts a classic tin vein system in a greisened intrusive; it features underground workings and a historical (non-compliant) resource. Additionally, on completion of the Amalgamation, the Company will inherit a small processing facility in Slovakia owned by the Target. Its inclusion in our strategic narrative underscores our commitment to efficiency and innovation, making it a key differentiator in today's market.

With global demand for antimony soaring and critical mineral supply chains becoming increasingly strained geopolitically, Military is seeking to take advantage of a strategic opportunity to acquire an asset that can fill this global demand.

MIlitary Metals $MILIF $MILI

Map showing the location of Military's properties in Slovakia

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10818/228324_9c2d07525482cbe0_002full.jpg

The technical contents of this release were reviewed and approved by Avrom E. Howard, MSc, PGeo, geological consultant to Military Metals and a qualified person as defined by NI 43-101.

MIlitary Metals $MILIF $MILI

NASDAQ: CRDL Rating & Price Target: H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.

New Trial: MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis (RP) patients post-IL-1 blocker therapy.

Market Advantage: CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.

Strategic Expansion: By targeting unmet needs in the RP market, CardiolRx is positioned to broaden its market potential.

Please see my other recent posts for more information on Taboola, there has been alot of recent news coming out, links immediately below...
Note: This announcement, the National World announcement, and the Abby announcement all came just before or after they announced their earnings date which will be pre-market 11/7/2024.

Taboola announces New Partnership with National World and Axiom Media Alliance https://www.reddit.com/r/pennystocks/comments/1g8rkeo/taboola_tbla_news_update_october_21_2024_taboola/

Taboola introduces Abby it’s AI Advertising Agent https://www.reddit.com/r/pennystocks/comments/1g48gim/taboola_introduces_abby_an_industry_first/

Taboola Native Advertising and Strategic Partnerships detailing strategic partnerships with Apple, Associated Press, Microsoft, Time, & Yahoo. https://www.reddit.com/r/pennystocks/comments/1ec1wt9/taboola_tbla_native_advertising_and_strategic/

What is Taboola? Taboola (NASDAQ: TBLA) is a leading content discovery platform that powers personalized recommendations for the open web. Known for its partnerships with major digital properties like Yahoo, CNBC, and BBC, Taboola’s platform reaches nearly 600 million daily active users. With 18,000 advertisers utilizing their AI-driven recommendation system, Taboola enables brands to reach audiences across a variety of websites, mobile apps, and digital devices, helping drive both engagement and revenue.

Recent News: Taboola’s Creative Shop Surpasses Four Years, Reports Strong Growth

Overview of the Creative Shop Milestone: On October 30, 2024, Taboola announced that its Creative Shop, an in-house service designed to support and optimize advertiser campaigns, has surpassed four years of operation. This service has become an essential tool for more than 800 top global brands and agencies, including Bombas, eToro, and NerdWallet. In 2024 alone, campaigns that involved the Creative Shop saw an 88% increase in conversion rates. Additionally, the number of advertiser campaigns supported by the Creative Shop increased by 43% from Q1 to Q2, reflecting rapid adoption and growth.

The Creative Shop provides Taboola’s clients with a full-service creative team—including data analysts, content strategists, copywriters, graphic designers, and video editors—that leverages data from hundreds of thousands of successful campaigns. This team helps brands tailor their advertising strategies, create optimized assets, and perform A/B testing, all aimed at boosting both brand awareness and performance-based results.

Supporting Testimonials:

• NerdWallet: The NerdWallet team highlighted the value of the Creative Shop’s insights, emphasizing how it has helped them align creative assets with strategic objectives while safeguarding their brand values.
• Enpal: Alina Bart, Head of Growth Marketing, stated that the Creative Shop brings a fresh perspective to their campaigns, providing actionable insights that her team found instrumental in pushing creative boundaries.
• EarPros (Amplifon Group): EarPros reported that working with Taboola’s Creative Shop led to a 59% reduction in cost per lead (CPL) in the U.S., helping them unlock additional budget and scale up campaigns.

Business Model & Growth Potential

Taboola’s business model focuses on driving monetization and engagement for publishers and advertisers by providing personalized content recommendations. With its Creative Shop and other offerings, Taboola offers advertisers access to a massive audience along with tools to optimize campaigns, potentially leading to higher ad engagement and conversion rates.

Key Growth Metrics:

• 88% increase in conversion rates for Creative Shop advertisers in 2024.
• 43% growth in campaign volume from Q1 to Q2 in 2024, highlighting the growing demand for Taboola’s services.
• 600 million daily active users across Taboola’s platform.

Advantages for Advertisers: Taboola's Creative Shop is a valuable resource for brands looking to maximize ad effectiveness on the open web. With in-depth campaign analysis and tailored creative assets, Taboola helps advertisers achieve higher conversion rates and cost efficiency, as demonstrated by its clients’ success stories.

Risks to Consider

1. Intense Competition: Taboola operates in a highly competitive environment, going head-to-head with Outbrain and Google AdSense. Its success depends on continued innovation and the ability to maintain partnerships with major publishers.
2. Regulatory Environment: Privacy regulations like GDPR and potential changes in digital advertising laws pose a risk for Taboola, which relies on data-driven advertising. Compliance with these laws can impact operational flexibility and profitability.
3. Market Sensitivity: Despite strong fundamentals, Taboola’s stock may be subject to volatility based on overall market sentiment, particularly in the ad tech sector.

Conclusion

Taboola’s latest announcement highlights the growing success of its Creative Shop, which has proven valuable to top brands looking to improve campaign performance. The increased conversion rates and campaign volume illustrate that Taboola’s service resonates well with advertisers. By combining AI-driven recommendations with a dedicated creative team, Taboola is positioning itself to remain competitive in a crowded ad tech space.

With the Creative Shop’s demonstrated success, Taboola appears to have carved out a valuable niche that could continue to drive growth, especially as advertisers seek effective ways to navigate the open web. However, competition and regulatory risks remain key factors to monitor.

Summary: Taboola’s Creative Shop, a service that provides advertisers with creative and strategic support, has hit new milestones. In 2024, campaigns using this service saw conversion rates increase by 88%, and the number of campaigns grew by 43% from Q1 to Q2.

Yesterday GRRR issued a press release which include several positive updates, yet the stock barely moves and seems undervalued. Updates include:

• Market cap of around $48 million yet has cash on hand of $40 million.
• Gorilla projects 2024 revenues to reach $72 million, with an EBITDA margin of over 20%, and net income of over $10 million. This builds on the momentum of 2023 and H1 2024, where Gorilla achieved a 222% increase in revenue and 456% growth in gross profit. Gorilla's backlog (i.e. signed contracts) going into 2025 now stands at $93 million, providing a solid foundation for sustained growth.
• Looking ahead to 2025, Gorilla projects revenues to surpass $90 million, with net income exceeding $15 million. The company is targeting EBITDA margins of 20-25%, further solidifying its financial stability and long-term profitability.
• Gorilla remains actively engaged in its share repurchase program, having acquired 1.1 million shares in September 2024. With $3.8 million of the $6 million authorized already utilized, the company is committed to continuing the buyback, confident that the current stock price does not reflect its true value.
• Gorilla's projections do not account for any impact from additional large-scale contracts. Following the Company's transformative MENA project win in 2023, Gorilla is pursuing additional projects in the AI-powered analytics, cybersecurity and smart city sectors. Some of these contracts are in advanced stages of discussions and valued in the hundreds of millions.

𝑻𝒂𝒍𝒌 𝒂𝒃𝒐𝒖𝒕 𝒚𝒐𝒖𝒓 𝒅𝒂𝒊𝒍𝒚 𝒑𝒍𝒂𝒚𝒔 𝒂𝒏𝒅 𝒄𝒐𝒎𝒎𝒆𝒏𝒕 𝒐𝒓 𝒑𝒐𝒔𝒕 𝒕𝒉𝒊𝒏𝒈𝒔 𝒉𝒆𝒓𝒆 𝒕𝒉𝒂𝒕 𝒅𝒐 𝒏𝒐𝒕 𝒘𝒂𝒓𝒓𝒂𝒏𝒕 𝒂𝒏 𝒂𝒄𝒕𝒖𝒂𝒍 𝒑𝒐𝒔𝒕.

​

𝒌𝒆𝒆𝒑 𝒊𝒕 𝒄𝒊𝒗𝒊𝒍 𝒑𝒍𝒆𝒂𝒔𝒆

If you watched $DRUG's explosive growth, $TVGN might be one to keep on your radar. In the last few months, Tevogen Bio ($TVGN) has seen a notable upswing, with a rise of over 120% due to a series of strong announcements. Securing Nasdaq compliance signals their financial stability, and their recent Letter of Intent with CD8 Technology aims to expand T-cell therapies—a sector with substantial investor interest and growth potential.

In addition, their AI arm, Tevogen AI, is driving innovation in drug discovery, mirroring trends that have propelled similar biotech companies. With these moves, some investors speculate that $TVGN could realistically hit double figures in the near term, potentially achieving a trajectory similar to $DRUG's path of rapid growth and market expansion.

Looking to hear y'all thoughts on this!

Source: StockTitan

• IBRX had some very strong 20% days
• I expect UK approval as next catalyst and/or a partnership
• Whether today's pullback is normal/healthy? I think so.

==========================================

EF Hutton analyst Jason Kolbert initiates coverage on Immunitybio Inc (NASDAQ: IBRX) with a Buy rating and a price target of 30$

============ AND ===============

https://finance.yahoo.com/news/first-patients-dosed-phase-1-130000535.html

• Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors
• First natural killer cell-based cellular therapy study conducted in the continent of Africa
• Complete enrollment currently expected in Q1 2025
  • PR seems meaningless
    • Combined PR's seems coordinated. For IRBX to raise they would need a much higher SP/MC.
    • It would not surprise me if the next PR is UK approval for Anktiva and a partner, securing funding

===========

• 50 Million Short
• 30% Of float
• 27 days to cover
  • Reason: Lack of liquidity/partner
  • Short seller problem: A very very very coy Dr. and billionaire CEO

===================================

Background

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

• Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2^(nd) and 3^(rd) line NSCLC cancer patients who progressed on checkpoint inhibitors such as KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab)
• ANKTIVA plus KEYTRUDA or OPDIVO rescued T cell activity in these patients who progressed on the same checkpoint inhibitor with overall survival of 57% at 12 months
• Long-term survival was independent of PDL1 tumor status and independent of 2^(nd) or 3^(rd) line of therapy
• The data continues to validate the mechanism of action of ANKTIVA in activating NK, CD8 killer, and Memory T cells resulting in prolonged overall survival in patients with advanced cancers
• Data supports global launch of Phase 3 randomized control of ResQ trials of ANKTIVA plus KEYTRUDA or OPDIVO in 1^(st) and 2^(nd) line NSCLC (ResQ301 and ResQ302) versus standard of care

=======================================================================

8/9/2024

Bio Investments can be extremely risky. Once in a while we see a unique company pursuing unique science with massive potential.

• Immunity Bio's Anktiva a new blockbuster
  • ANKTIVA, developed by ImmunityBio, has received FDA approval for use in combination with BCG (Bacillus Calmette-Guérin) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This drug leverages the immune system, particularly by stimulating natural killer (NK) cells and T cells, to fight cancer, offering a promising new treatment option for patients who previously faced invasive surgery
  • ANKTIVA is also being investigated for multiple other conditions, including various solid tumors, non-Hodgkin's lymphoma, non-small-cell lung cancer, and HIV
• Immunity Bio Finances at a glance
  • ImmunityBio is experiencing deficit and cash-flow challenges, according to the filing. As of June 30, the company had an accumulated deficit of $3.2 billion. It also had negative cash flows of $207.3 million during the six months ended June 30.
  • The company also said in the filing that it believes there is substantial doubt about its ability to continue without additional funding. However, it went on to note that its existing cash, cash equivalents and investments in marketable securities; sales of approved product; capital to be raised through equity offerings; and potential ability to borrow from affiliated entities will fund operations through at least 12 months.
• Understanding the CEO
  • Soon-Shiong's net worth is $6.2 billion as of 2024. He has been called the richest man in Los Angeles and one of the wealthiest doctors in the world.
  • Soon-Shiong purchased Fujisawa, which sold injectable generic drugs, in 1998. He used its revenues to develop Abraxane, which took an existing chemotherapy drug, Taxol, and wrapped it in protein that made it easier to deliver to tumors. He was able to quickly move it through the regulatory process and made his fortune with this medicine
    • https://en.wikipedia.org/wiki/Patrick_Soon-Shiong#References
• ImmunityBio Strategic partnership in India.
  • Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatment for non-muscle invasive bladder cancer (NMIBC)
  • Serum Institute of India (SII) will manufacture both standard BCG (“sBCG”) and next-generation recombinant BCG (“iBCG”), creating a long-term solution to chronic BCG supply shortage issues
• Next indication approval
  • ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
    • QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2^(nd)– and 3^(rd)-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy.
    • Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC
    • Data reaffirms the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types
• Presentation TODAY (08/09/2024)

  • Results: The median OS (n=86) was 14.1 months (95% CI 11.7, 17.4) with 24 ongoing survival to date. In 3^(rd) line+ve (n=25) median OS was 14.8 months (95% CI 9.1, 26.7). OS for PDL1+ve (>1%) (N=53) was 13.8 months (95% CI 10.2, 17.4) versus PDL1-ve (N=33) blah blah blah......... https://cattendee.abstractsonline.com/meeting/20598/Session/142Conclusions: Anktiva plus CPI therapy in 2nd line or greater NSCLC demonstrated long-term median OS, independent of PDL1 status, and independent of prior lines of therapy in patients with acquired resistance to CPI. These findings support the novel mechanism of action of Anktiva to rescue CPI activity through the activation of NK and T cells, driving long-term memory, with median OS ongoing survival of 33% and 30% at 18 and 21 months respectively, exceeding the standard of care.

Lastly, there is always a risk of dilution here. But, it is a long hold anyway.

I recently came across Delta Resources and have been sharing their Delta-1 project, a gold exploration site just west of Thunder Bay, Ontario. What’s fascinating is that this project sits within the Shebandowan Greenstone Belt, a region historically known for its copper, nickel, and even platinum-group elements, but with untapped gold potential. Delta Resources’ team saw what others missed and, since 2019, has set out to unlock this hidden wealth. 

The region’s story goes back decades with early explorations by large companies like Inco, who found promising gold deposits yet left them largely unexplored due to corporate changes, namely being bought out by Brazilian bemouth Vale for almost $20B. Some of the early findings were remarkable — grades such as at the IZone with results yielding 3.28 g/t gold over 14.6 meters, 4.32 g/t Au over 41meters, 4.53 g/t Au over 14.4meters, and 4.36 g/t Au over 20.4 meters. But with a major corporate shift, the gold discoveries were put on the back burner, waiting for someone like Delta to pick up the torch. 

Since then, Delta’s exploratory drilling has revealed high-grade mineralization, proving this isn’t just speculation. Recent intercepts at the Eureka deposit on the same property package yielded drill results like 5.92 g/t gold over 31 meters and 72.95 g/t gold over 2.2 meters confirming the deposit’s economic potential. By 2024, their drilling campaign hit more standout grades at Eureka, like 15.94 g/t over 10 meters. Plus, the Eureka Gold Deposit’s strike length now spans 2.5 kilometers and the deposit has also been drilled to a depth of 300 meters from surface and remains open in every direction. Eureka is already a major discovery and the very large property package still remains to be explored. 

Delta’s relentless drive and successful results have earned them significant recognition, like the Bernie Schnieders Discovery of the Year Award in 2022 for the Province of Ontario, Canada. I genuinely think they’re onto something big here, and it could be just the beginning of Delta-1’s story in Ontario’s greenstone gold belt. 

Disclaimer: This is not financial advice. Please do your own research before investing. 

VDRM is shipping 1,000,000 units of vitastem to Nigeria. Read my earlier post to see how I justified the $1.5/share and $53M 2025 revenue. From this shipment alone, a potential of +8800% YoY for VDRM revenue!

https://www.reddit.com/r/pennystocks/comments/1gcl3f8/vdrm_estimated_stock_price_in_2025_150229_w/

Vitastem's (topical antibiotic) main ingredient is bacitracin zinc, which is super effective against Staphylococcus Aueus (staph infection) and other skin based bacterial infections.

Staphylococcus Aueus has developed a strong resistance to most common antibiotics in Nigeria called AMR (antimicrobial resistance). AMR is the 3rd leading cause of death in Nigeria. Most highly effective prescription drugs for severe Staph are scarce and very expensive in Nigeria.

This means there is a real need and gap that Vitastem is filling in Nigeria!

On October 20, 2024, WHO and Nigerian health officials were drastically increasing awareness and education for the local population for misuse of common antibiotics that are no longer effective in Nigeria. This also includes appropriate use of over-the-counter antibiotics that are still effective, like bacitracin zinc. They also want to encourage local poulation to get early diagnosis by local medical professionals to prevent these infections from escalating to the need of rare and expensive drugs.

There is a real demand for Vitastem in Nigeria, and it might ensure a steady demand for the drug in Nigeria for many years. This will likely prove very profitable for VDRM and shareholders in 2025 and for many years to come.

NOTE: Don't solely base your investment decisions on my post alone. Do you own research before investing money into any stock. Penny stocks are risky. My research and calculations are done with good faith, but are speculative and should not be taken as garunteed.

Source:

https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Completes-First-Shipment-of-500000-Units-to-Nigeria?id=452594

https://www.healthdata.org/sites/default/files/2023-09/Nigeria.pdf

https://getvitastem.com/pages/staph

https://www.afro.who.int/countries/nigeria/news

Peraso, Inc. Investment Summary:

Q2 2024 Results: $4.2 million in revenue, with mmWave revenue up 180%.

Tech Leadership: Focused on mmWave since 2009; market expected to grow at 40% CAGR to $55 billion by 2030.

Growth Initiatives: Targeting NRE revenue, military contracts, and BEAD funding.

2025 Outlook: Projecting $16 million in revenue, driven by 150% growth in mmWave.

Valuation: Price target of $3.75 based on a 3x revenue multiple.

Financial Overview:

Cash Position: $2 million; recent fundraising of $6.4 million.

Memory Product Phase-Out: Anticipated $9-10 million revenue loss in 2025.

I don’t understand why this isn’t talked about more because the mission of this company is critical to the survival of humanity, and they are producing SERIOUS RESULTS.

If we, as a species, do not systemically decarbonize, then we continue to feed the multi-trillion dollar existential disaster that is climate change.

LODE is taking action TODAY by producing a green, sustainable, drop-in replacement fuel for aviation, diesel, gasoline, and other fossil fuel applications. They’re achieving an industry-shattering yield of 120 gasoline gallon equivalents per ton of landfill-destined woody waste feedstocks, doubling the yield of any would-be competition. This uses mature and third-party verified technology.

LODE is recycling and reusing toxic, landfill-bound solar panels at an impressive rate—one large panel recycled every seven seconds.

LODE is recycling and reusing lithium batteries.

LODE is practicing sustainable mining and has received multiple environmental stewardship awards for their practices.

The list of accomplishments goes on.

The only thing standing between these guys and systemic global change is lack of awareness.

In the future, we could fill our gas tanks with cost-parity Bioleum instead of filthy fossil fuels!

Let your voice be heard!

They are in a fast growing industry and they focused to increase their clients portfolio than their profit margins. They have also diluted at $0.60. Now the share price is around $0.18. Underfollowed stock, they confirmed their previous guidance which is good.

Financial Highlights for Fiscal 2024

• Net revenue for the fiscal year ended June 30, 2024 grew by 72% to $48.52 million, up from $28.23 million in 2023.
• Gross profit increased by 33% to $2.75 million for the fiscal year ended June 30, 2024 from $2.06 million in the fiscal year ended June 30, 2023.
• Net income grew by 33.0% to $1.29 million for the fiscal year ended June 30, 2024, up from $0.97 million in the fiscal year ended June 30, 2023.

Cardiol Therapeutics (CRDL) Sales Multiples:

Recurrent Pericarditis: Valued at $9 per share, assuming $609M in sales by 2033 with a 60% probability of success.

Acute Myocarditis: Valued at $1 per share, assuming $132M in sales by 2033 with a 40% probability of success.

Cash Considerations: No value attributed to forward year 1 cash.

Risks: Key risks include the potential failure to meet clinical endpoints, delays in regulatory approvals, and competitive pressures affecting market adoption and pricing.

This approach aligns with industry standards, utilizing a 3x sales multiple and a 9% WACC.

https://imgur.com/aplynv1

CLNV confirming Dan Bates is in West Virginia with UPSIS beginning the engineering of the facility. Dan Bates has a space call on Thursday and the funding is supposed to hit before November. It's OCT 29th, and Dan is in West Virginia with UPSIS.

LOS ANGELES, CA / ACCESSWIRE / September 23, 2024 / Clean Vision Corporation (OTCQB:CLNV) ("Clean Vision" or the "Company"), an emerging leader in innovative plastic recycling and clean fuel development, is proud to announce that its wholly owned subsidiary, Clean-Seas West Virginia, Inc. ("Clean-Seas West Virginia"), has signed an agreement with UPS Industrial Services, LLC ("UPSIS") for the engineering, procurement, and construction ("EPC") of its plastic conversion facility in Quincy, West Virginia. The project is scheduled to commence in the fourth quarter of 2024, with full operations expected by August 2025.

Clean-Seas West Virginia's facility is expected to draw in plastic feedstock from across the Mid-Atlantic region and convert what might otherwise end up in landfills, incineration or our oceans into valuable, clean fuels. This facility is part of the Company's expanding Plastic Conversion Network ("PCN") portfolio of global plastic conversion projects, which includes current initiatives in India and Morocco.

According to industry Grand View Research, the global plastic pyrolysis market is projected to reach $2.7 billion by 2030, growing at a compound growth rate (CAGR) of 26.1% from 2024 to 2030. In the Company's view the rise in environmental awareness, along with increasing government regulations aimed at reducing plastic waste, is driving demand for sustainable technologies like those deployed by the Company.

"We are thrilled to partner with UPSIS, a leader in EPC services, to help bring our first US- based project to life," said Dan Bates, CEO of Clean Vision Corporation. "USPSIS' expertise and commitment to quality make them the ideal partner to help us achieve our goal of launching the West Virginia facility and developing our PCN into a global source for clean fuels and environmental responsibility."

Lonnie Jackson, Senior Project Director, echoed the sentiment, "UPSIS is proud to be part of this groundbreaking project with Clean-Seas West Virginia. This facility is a testament to the innovative solutions required to tackle the world's plastic pollution problem, and we are committed to delivering a project that meets the highest standards of safety and operational excellence."

As part of the EPC agreement, UPSIS will oversee the engineering and construction of the West Virginia facility located in Quincy, West Virginia, as well as obtain a Performance & Payment bond, aimed at ensuring the project's successful delivery. Current plans are for project financing to be led by a regional bank dedicated to supporting projects focused on the economic growth of West Virginia and sustainable development. We are currently planning for this a financing to be completed in October 2024, with groundbreaking for the facility upgrade shortly thereafter.

This innovative facility, designed to convert plastic feedstock into clean fuels through the process of pyrolysis, represents what we believe is a significant step towards addressing the global plastic waste crisis. Supported by the multiple agencies within the West Virginia State Government, including the Department of Economic Development and the Economic Development Authority, this project underscores West Virginia's commitment to sustainable innovation and economic growth.